The story of Sildenafil presents a intricate picture for shareholders. While the initial launch generated massive returns, the expiration of its intellectual property protection opened the door to off-brand alternatives, dramatically diminishing sales. This presents a unique challenge for drug manufacturers relying on similar blockbuster medication

The story of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in income, its intellectual property lapse created a deluge of lower-priced alternatives , significantly diminishing its dominance. While some businesses may try to capitalize on similar conditions , the